anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to an application of Indinavir used as chloroquine resistant reversal agent or chloroquine synergist in the preparation of a medicinal composite for curing malaria. The different concentration ratios between the Indinavir and the chloroquine in the cellular level detection ranges from 1:100 to 100:1, have synergistic effect to a sensitive strain 3D7, and a chloroquine drug-resistant strain Dd2, and show stronger synergistic effect to the chloroquine drug-resistant strain. In the model of Plasmodium chabaudi infection of a mouse, the standard 4-day suppressive test is adopted, with the discovery that the chloroquine antimalarial activity synergy of the Indinavir exhibits more obviously on the chloroquine drug-resistant strain. After the treatment, the composite medicine containing 100mg/kg of chloroquine and 1.8mg/kg of Indinavir can completely clear the chloroquine resistant strains of the Plasmodium chabaudi of the mouse, and the negative conversion rate of the plasmodium is 100 percent. The total dosage of the composite medicine applied to prevent and cure human malaria is as follows: 12mg/kg to 100mg/kg of the chloroquine and 60mg/kg to 500mg/kg of the Indinavir. The invention develops a new composite antimalarial and provides a foundation for the reapplication of the economical and practical chloroquine in the malaria treatment.
Patch for continuous administration of a controlled amt. of ointment contg. nitroglycerin to skin or mucosa comprises a backing member with a peripheral releasable skin adhesive layer on one face, a release layer over the adhesive and inwardly of the adhesive a graduated scale to facilitate dispensing of an ointment dosage. The adhesive pref. covers one face of the member, and the scale is carried on a separate layer which is attached to the adhesive. The scale may be formed by two linear markings spaced from each other by at least the width of a ribbon of ointment dispensed from a tube and having diff. graduations. The backing is pref. of plastics film and the release layer is of paper carrying a release agent.
In this study, it is aimed to develop the open heart surgery patient care protocol and to examine its effect on the pain that develops after sternotomy. The research is planned to be carried out on the patients in the Cardiovascular Surgery Intensive Care Unit of Research Hospital. The sample size of this study was decided by power analysis. The G-Power statistics program is based on Type 1 error 0.05 and 80% power. In the power analysis of Akbayrak and Tosun's (2002) thesis study, using the results showing the average score of the satisfaction level of the patients with and without the care protocol, the sample size was determined as 17 patients for each group and 34 patients in total. However, in order to meet the parametric test assumptions, it was decided to include at least 30 people in each group.
BACKGROUND: Low back pain is a major global health problem. Physiotherapy involving exercises is considered first-line treatment. In recent years digital tools including telerehabilitation have increased, but the interventions are diverse. The aim of this study was to map how telerehabilitation approaches are used in studies evaluating exercise-based rehabilitation in patients with chronic low back pain.
METHODS: A systematic literature search was conducted in PubMed, Cinahl and Cochrane Central between January 2017 and January 2024 for original studies on adults, 18 years or older, with chronic low back pain who received exercise-based telerehabilitation.
RESULTS: The database search resulted in 1019 articles. Out of 37 full texts that were screened 28 articles were included in the analysis. The included studies showed a wide variation regarding technological solutions, interventions and outcome measures. The exercise-based telerehabilitation was usually delivered asynchronously via a smartphone application. The most common clinical outcome measure was pain and disability/physical function. Telerehabilitation compared to conventional exercise therapy showed similar clinical improvements.
CONCLUSIONS: This scoping review confirms the heterogeneity within this research area but also contributes by mapping and demonstrating some knowledge gaps in the literature. Further research focusing on synchronous and group interventions are needed. The new technologies described in the included studies provide added value through functional improvements and task redesign.
TRIAL REGISTRATION: OSF https//doi.org/10.17605/OSF.IO/EMKCG.
ADHD is a neurologic disorder that is thought to be caused by chemical imbalances of certain neurotransmitters in the brain. The disorder can cause inattention, hyperactivity, and impulsivity. Cocaine abuse rates in adults with ADHD are significantly higher than they are in adults who do not have the disorder. This may be reflective of an attempt by individuals with ADHD to self-treat symptoms. Atomoxetine is an FDA-approved drug that is used to increase the ability to pay attention and decrease impulsiveness and hyperactivity in children and adults with ADHD. The drug is in a class of medications called selective norepinephrine reuptake inhibitors and works by increasing the levels of norepinephrine, a natural substance in the brain that affects a person's attention and impulsivity. It is possible that reducing ADHD symptoms in cocaine abusers with ADHD will help decrease their need for cocaine. This study will evaluate the effectiveness of atomoxetine in reducing cocaine use in people with ADHD who abuse cocaine.

Participants in this open label study will receive atomoxetine for 12 weeks, and will take one dose each morning for the duration of the study. Doses will be increased gradually to minimize side effects and enhance treatment compliance. In addition, all participants will receive individualized relapse prevention therapy once weekly. Participants will be required to report to the study site three times a week to receive medication, complete questionnaires regarding ADHD symptoms and substance use behavior, and provide a urine sample while being supervised by study staff. Also, vital signs will be monitored and medication side effects will be assessed at each visit. Participants will report to the study site 6 months after starting in the study for a follow-up visit, at which time ADHD symptoms, substance use behavior, and social functioning will be assessed.
The utility model discloses a synthetic drug production system, which comprises a fresh ethanol storage tank arranged at the front end, wherein the rear end of the fresh ethanol storage tank is connected with a first delivery pump through a pipeline, and the rear end of the first delivery pump is connected with a first reaction kettle and a second reaction kettle through a pipeline; a first condenser is arranged on the first reaction kettle, a second condenser is arranged on the second reaction kettle, and the rear ends of the first reaction kettle and the second reaction kettle are connected with a centrifugal machine through pipelines; the rear end of the centrifuge is provided with a double-cone dryer, and the rear end of the centrifuge is connected with an ethanol mother liquor ground tank through a pipeline. The rear end of the ethanol mother liquor ground tank is connected with a distillation kettle through a pipeline. And the rear end of the distillation kettle is provided with a third condenser through a pipeline. The rear end of the third condenser is respectively connected with a high-low boiling storage tank and a recovered ethanol storage tank through pipelines. And a second delivery pump is arranged on a pipeline at the rear end of the recovered ethanol storage tank. The production system has high production efficiency and improves the utilization rate of products.
BACKGROUND: While recent studies have suggested a potential involvement of circRNAs in acute kidney injury (AKI) after ischemia, mmu_circ_003062 role is undetermined.
METHODS: The levels of mmu_circ_003062, miR-490-3p, CACNA1H, GRP78, CHOP and hsa_circ_0075663 were detected by Relative qPCR in Boston University mouse proximal tubule (BUMPT) cells, mouse kidneys, and human renal tubular epithelial (HK-2) cells. Moreover, the levels of hsa_circ_0075663 in serum and urine of patients with AKI following cardiopulmonary resuscitation (CPR) were detected by absolute quantitative PCR. Western blot was used to detect the relative expression of the protein. The function and regulatory mechanism of mmu_circ_003062 and hsa_circ_0075663 were investigated through a series of in vitro and in vivo experiments, including bioinformatic prediction, luciferase reporter assays, FISH, FCM, TUNEL staining, and H&E staining.
RESULTS: It was found that mmu_circ_003062, hsa_circ_0075663 mediated apoptosis after ischemia/reperfusion (I/R) by interaction with miR-490-3p to enhance CACNA1H expression, thereby leading to the upregulation of endoplasmic reticulum stress (ERS)-relevant proteins GRP78 and CHOP. Ultimately, mmu_circ_003062 downregulation significantly ameliorated ischemic AKI by modulating the miR-490-3p/CACNA1H/GRP78 and CHOP pathway. Furthermore, the plasma and urinary levels of hsa_circ_0075663 in patients with AKI following CPR were significantly higher than non-AKI patients, exhibited a strongly correlation with serum creatinine.
CONCLUSION: The involvement of mmu_circ_003062, hsa_circ_0075663/miR-490-3p/CACNA1H/GRP78 and CHOP axis is significant in the development of ischemic AKI. Moreover, hsa_circ_0075663 has potential as an early diagnostic biomarker.
The present invention discloses a composite material for the deletion repairing of a tooth and the human hard tissue and a preparation method thereof. An inorganic phase of the composite material is an oxide partial calcination ceramic body, and an organic phase is a monomer containing vinyl double keys and (or) a polymer which is obtained by oligomer polymerization. The preparation method comprises the following steps of partial calcination ceramic preparation, the surface coupling processing of the partial calcination ceramic body, and the vacuum impregnation and in-situ polymerization of resin. The composite material has the advantages of good mechanical performance and good toughness. Bending strength, elastic modulus and fracture toughness can be regulated according to the requirements. CAD/CAM processing can be carried out at the partial calcination body phase, and CAD/CAM system processing can be carried out after the composite material is prepared. The composite material can be used as dental repairing materials comprising artificial teeth, inserting bodies, single tooth crown and crown bridge combination bodies and can be used as a hard tissue repairing material comprising load bearing bone substitutes, artificial knee joints and artificial hip joints.
Nebulizer systems, adapters, methods, and apparatuses are described for a nebulizer adapter that includes a body, an inlet for aerosolized respiratory medications and/or medical marijuana and/or other pharmaceuticals, a breathing gas inlet tube and outlet tube, a barrier or body, and a drain lumen port that passes from the bottom of the barrier or body of the apparatus to the exterior into a port drain. The port drain would be in fluid communication with a receptacle removably attached to the annular lid that is attached to the bottom of the adapter body for collecting condensed moisture, wherein the receptacle comprise an actuator member configured to actuate the airtight seal of the annular lid upon attachment. The adapter includes a sensory system and temperature regulating system that continuously detects and regulates the temperature within an adapter to minimize condensates from forming and interfering with patient care. A computation device also stores individual patient outcomes and corresponding sensory information and accesses stored aggregate individual patient outcomes and corresponding sensory information from other sensory systems, wherein a machine learning algorithm utilizing quantum computing compares current individual patient sensory information, stored aggregate patient outcomes, and corresponding sensory information from other sensory systems to automatically predict statistical likelihoods of patient outcomes and automatically generate possible treatments and suggested diagnosis, wherein said display screen can access and display said statistical likelihoods of similar patient outcomes and automatically generated possible treatments and suggested diagnosis. An optional drainage system suctions condensate into a drainage port using mechanical energy produced by the internal force of a spring. There is a display screen where hospital workers and telemetry units can access the sensory information, alert notifications to hospital personnel, and manually override if necessary.
The participants will be recruited at companies in the Swedish office sector, and after recruitment and baseline assessment, the participants will be randomly assigned to one of two groups Healthy Lifestyle (HL) or Sustainable Lifestyle (SL).

All participants will complete web-based questionnaires including background information about weight, height, diet, physical activity, smoking, education and other relevant background variables at the beginning of the study as well as at the end of the study. Participants will attend separate group-based workshops 6 times during the 8-week intervention period held by trained personnel. During these workshops, participants will be guided by education, food provision, and assistance to identify facilitators and barriers to a healthy or sustainable lifestyle. In addition, adherence to a healthy or sustainable lifestyle will be reinforced using a behavioral support package provided through a digital platform during the intervention period.

We will compare baseline, midpoint, and final (i.e. week 0, 4 and 8) nutrient intake, CO2e, and the dietary sustainability score for the two diets with an ANOVA model. We assume a dropout rate of 10-15% after baseline assessment (based on our previous pilot study from the fall of 2017) Climate Friendly and Ecological Food on Microbiota (CLEAR). Therefore, we will recruit 47 people to each group to have at least 40 at the end of the study. With 40 participants in each group, this analysis has \>90% power to detect a 50% reduction in CO2e for the intervention group. To gain further insight into the development of intake of nutrients, CO2e, and the dietary sustainability score during the follow-up, we will use linear mixed models, with individual-specific baseline trajectories. Moreover, we will perform substitution analyses, i.e. scenarios where a number of meals high in CO2e are substituted for meals low in CO2e. Statistical analyses will be done in R-statistics.
BACKGROUND: Nonmanual room disinfection systems may reduce the transmission of infections. A variety of systems have emerged; however, a paucity of evidence exists to make an evidence-informed decision for the implementation of a specific system. Alberta Health Services assessed one of these systems.
METHODS: A quasi-experimental prepost design assessed an aerosolized hydrogen peroxide disinfection system on 6 units at 3 acute care facilities in Alberta. To assess clinical effectiveness an interrupted time-series analysis with Poisson distribution compared changes in hospital-acquired Clostridioides difficile infection (HA-CDI) and hospital-acquired Methicillin-resistant Staphylococcus aureus (HA-MRSA) between preintervention, intervention, and postintervention periods. To assess operational feasibility cleaning turnaround time, time to operate, and utilization were considered. A participatory research framework was used to understand the benefits and challenges of operationalization.
RESULTS: Incidence rate ratio (IRR) of HA-CDI decreased by 25.7% on FMC-A and 6.9% on RAH-B. Following withdrawal, the IRR of HA-CDI continued to decrease. IRR of HA-MRSA decreased by 25.0% on RAH-B. Following withdrawal, the IRR of HA-MRSA continued to decrease. None of the results were statistically significant. The average time to operate was 3.2 hours. Utilization was between 1.7% and 25.6%. Most staff reported benefits and challenges.
DISCUSSION: None of the changes observed in HA-CDI and HA-MRSA after the introduction of the aerosolized hydrogen peroxide system were statistically significant. While most respondents reported multiple benefits and challenges in using the system, the core challenge was delays in inpatient admissions due to the time operate the system.
CONCLUSION: Successful implementation of a nonmanual room disinfection system as an addition to standard cleaning and disinfection requires significant investment and must consider a variety of factors.
A topical ectoparasiticide composition comprising: i) an Insect Growth Regulator (IGR) and/or a phenyl pyrazole insecticide; and/or a chloronicotinyl insecticide; ii) glycol ether; and iii) butanol and/or dimethylsulfoxide (DMSO). The preferred IGRs include hydroprene, s- hydroprene, kinoprene, s-kinoprene, fenoxycarb, pyriproxifen, cyromazine, dimilin and novaluron, especially methoprene or s-methoprene. The preferred phenyl pyrazole insecticide is fipronil. Preferably, the chloronicotinyl insecticide is imidacloprid and/or thiacloprid. The preferred glycol ether is diethylene glycol monoethyl ether. The composition may also comprise a crystallization inhibitor and/or a surfactant and/or an antioxidant and/or a propellant. The composition is useful for the treatment for the reduction or inhibition of juvenile ectoparasite maturation from the skin of an animal.
After providing opt-in electronic consent, eligible consented participants will be randomized to one of two hypothetical genetic testing scenarios (rare, life-altering genetic condition or common, life-threatening genetic condition). The genetic testing scenarios include brief detailed information about genetic testing (i.e. how results may influence treatment decisions) as well as information about standard approaches to treatment. Subjects will be randomized to receive a framing conditions (e.g. choice, opt-in, opt-out, enhanced choice). Participants will select a preferred testing option to the hypothetical scenario and will complete several validated instruments.
In the second stage, at least 250 patients with MM and 250 patients with NHL and at least 100 patients with each of the remaining hematological malignancies mentioned above will be tested. Out of these patients, AML, lymphoma and MM patients will be followed-up at the clinical sites. Periodic sampling will be defined according to disease type and progression rate. Blood and plasma samples will be stored in the clinical sites until relapse diagnosis. At this stage, blood samples will be analyzed retrospectively on the HemaChip. The screening, enrollment, and sample collection can begin in the first stage of the trial, in order to allow a maximum follow-up period for at-risk subjects as part of the study and to meet the recruitment goals.
PURPOSE:To obtain the porous body of calcium phosphate compd. preferable to the prosthesis of bones and teeth from an inexpensive raw material by kneading calcium compd., phosphate and nonvolatile organic liquid and thereafter molding this kneaded material and sintering the molded body. CONSTITUTION:Calcium compd., phosphate and nonvolatile organic liquid are kneaded and thereafter this kneaded material is molded and the molded body is sintered. As the calcium compd., calcium carbonate and calcium oxide are preferably utilized. As the phosphate, inorganic salt may be utilized, but organic phosphate such as monovalent phosphate (monoalkyl phosphoric ester), bivalent phosphate (dialkyl phosphoric ester) and tervalent phosphate(trialkyl phosphoric ester) is preferably utilized. In the above method, a mixture contg. calcium compd. and phosphate is calcined and this calcined body and the nonvoiatile organic liquid can be kneaded. As the nonvolatile organic liquid, aqueous liquid material of methyl cellulose, polyethylene glycol and PVA are preferably utilized. The kneaded material is preferably sintered at 600-1300 deg.C and the mixture is preferably calcined at 300-600 deg.C.
Patients treated with Simbrinza™ (brinzolamide 1%/brimonidine 0.2%) as standard of care in clinical practice. No study drug is administered in this study.
PURPOSE:To obtain an antibacterial composition showing excellently preventing effects on deterioration of pimples and treating effects on inflammations, containing baicalein phosphate as an active ingredient. CONSTITUTION:Baicalein phosphate, flavonoid of Scutellaria baicalensis, crude drug, is dissolved in any of various aqueous solutions by a conventional procedure and then prepared into a necessary dosage form to give the aimed substance. The aimed substance can be prepared into solution, cream, ointment, powder or spray. The substance is preferably blended with a buffer solution at pH approximately 5.0 in order to show the antibacterial action of phosphate at its maximum and the composition is preferably adjusted to pH 5.0-6.5. The aimed substance shows selectively antibacterial action on Propionibacterium, pimple causing bacterium. 0.2-8mug baicalein phosphate is applied based on 1cm<2> skin.
The invention relates to a novel lamellar molybdenum disulfide based nano immunologic adjuvant as well as a preparation method and application thereof. The immunologic adjuvant is a product obtained by modifying a molybdenum disulfide nano lamina by using CpG and PEG. The preparation method comprises: performing ultrasonic treatment on the molybdenum disulfide nano lamina; then mixing the molybdenum disulfide nano lamina with CpG and PEG, and performing temperature controlled incubation in a swing bed; and performing centrifugation to remove free CpG and PEG. The nano immunologic adjuvant provided by the invention is small in particle size, uniform in size, and large in specific area, has relatively strong near-infrared region photo-thermal conversion capability, and can improve the secretion level of immune activation related cell factors to a great extent in combination with infrared laser irradiation. Moreover, the nano immunologic adjuvant provided by the invention has relatively low cytotoxicity. The nano immunologic adjuvant provided by the invention has the advantages of low raw material cost, simple preparation process, good repeatability, stable performance and the like.
The invention concretely relates to a formula and a preparation method of a Hui Nationality traditional Chinese medicinal Cordyceps sinensis lung cancer treatment pill. The pill is a green high-tech Chinese herbal medicinal product used for treating the lung cancer. The pill is a traditional Chinese medicinal pill prepared through the following steps: mixing of Cordyceps sinensis, root bark of Araiia chinensis L., oysters, Thallus Laminariae, Herb of Sharpfruit Calanthodes, Chinese Sage Herb and other Chinese herbal medicines according to a certain ratio, water adding, decoction, extraction, concentration and pill preparation. The pill is mainly used for treating the lung cancer, and also is used for treating throat cancer, stomach cancer, colorectal cancer and other digestive system cancers. The pill has the characteristics of suitable medicine variety quantity and moderate dosage, and all the medicines are proved by modern medical science pharmacological experiments to be suitable for treating the cancers. The pill fundamentally improves the body functions, prevents condition exacerbation and recovers the health of bodies at a low cost.